CLRB Overview
Upcoming Projects (CLRB)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CLRB)
-
A Second Look: Discussing the top line results of Cellectar's CLOVER WaM of Iopofosine I-131 in Waldenstrom Macroglobulinemia
Ticker: CLRB
Executed On: Jan 26, 2024 at 01:00 PM EST -
Discussing the top line results of Cellectar's CLOVER WaM of Iopofosine I-131 in Waldenstrom Macroglobulinemia
Ticker: CLRB
Executed On: Jan 23, 2024 at 11:00 AM EST -
Evaluating the potential of Iopofosine I 131 (CLR131) SM radiotherapeutic from Cellectar for the development for Waldenstrom macroglobulinemia and the CLOVER-WaM trial
Ticker: CLRB
Executed On: Aug 03, 2023 at 01:00 PM EDT -
Evaluating the potential of new therapies in development for Waldenstrom macroglobulinemia with a focus on Iopofosine I 131 (CLR131) SM radiotherapeutic from Cellectar and mavorixafor from X4 Pharma
Tickers: CLRB, XFOR
Executed On: Sep 15, 2022 at 11:00 AM EDT
Expired Projects (CLRB)
-
Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy
Ticker: CLRB
Execute By: Mar 31, 2024 -
Discussing Cellectar Bio's (CLRB) main drug candidate, CLR 131, in light of its most recent data in Waldenstrom’s Macroglobulinemia
Ticker: CLRB
Execute By: Aug 24, 2021
Upcoming & Overdue Catalysts (CLRB)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CLRB)
-
Phase 2 of Cellectar Bio's (CLRB) CLR 131 in Waldenstrom’s Macroglobulinemia data to be presented at ASCO June 4, 2021
Ticker: CLRB
Occurred on: Jun 04, 2021 -
Cellectar Biosciences (CLRB) Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma
Ticker: CLRB
Occurred on: Mar 19, 2018 -
Cellectar Bio (CLRB) Phase 1 Data Evaluating CLR 131 in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Ticker: CLRB
Occurred on: Feb 27, 2017 -
Cellectar (CLRB) Initiates Fourth Cohort of Phase 1 Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma (rrMM)
Ticker: CLRB
Occurred on: Feb 22, 2017 -
Cellectar BioSciences (CLRB) Announces $8MM Public Offering
Ticker: CLRB
Occurred on: Nov 23, 2016 -
Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer
Ticker: CLRB
Occurred on: Jun 23, 2016 -
Cellectar Biosciences Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Published by USPTO
Ticker: CLRB
Occurred on: May 20, 2016
Strategic Initiatives (CLRB)
-
Cellectar Bio (CLRB) Announces Partnership with INC Research (INCR) for Phase 2 Trail Assessing CLR 131 in Multiple Myeloma and Select Hematologic Malignancies
Tickers: CLRB, INCR
Announcement Date: Nov 17, 2016
